Delivery systems for siRNA drug development in cancer therapy

Asian Journal of Pharmaceutical Sciences

Volumn 10, Issue 1, 2015, Pages 1-12

  Xu, Cong fei ^a   Wang, Jun ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer therapy; Delivery systems; RNA interference; SiRNA

Indexed keywords

NANOPARTICLE; POLYMER; SMALL INTERFERING RNA;

CANCER THERAPY; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; REVIEW; RNA VECTOR;

EID: 84923013790     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.08.011     Document Type: Review

References (99)

1. Fire A., Xu S.Q., Montgomery M.K., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Elbashir S.M., Harborth J., Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
3. Davis M.E., Zuckerman J.E., Choi C.H., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
4. Vaishnaw A.K., Gollob J., Gamba-Vitalo C., et al. A status report on RNAi therapeutics. Silence 2010, 1:14.
5. Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci 1978, 75:3327-3331.
6. Dominska M., Dykxhoorn D.M. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010, 123:1183-1189.
7. Alexis F., Pridgen E., Molnar L.K., et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
8. Layzer J.M., McCaffrey A.P., Tanner A.K., et al. Invivo activity of nuclease-resistant siRNAs. RNA 2004, 10:766-771.
9. Van de Water F.M., Boerman O.C., Wouterse A.C., et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006, 34:1393-1397.
10. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
11. Larson S.D., Jackson L.N., Chen L.A., et al. Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery 2007, 142:262-269.
12. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67.
13. Schultz N., Marenstein D.R., De Angelis D.A., et al. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-pathway and reveal microRNA regulation of TGFBR2. Silence 2011, 2:1-20.
14. Hornung V., Guenthner-Biller M., Bourquin C., et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005, 11:263-270.
15. Judge A.D., Sood V., Shaw J.R., et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462.
16. Karikó K., Bhuyan P., Capodici J., et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004, 172:6545-6549.
17. Marques J.T., Williams B.R. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005, 23:1399-1405.
18. Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
19. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
20. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
21. Deleavey G.F., Damha M.J. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 2012, 19:937-954.
22. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
23. Malek A., Merkel O., Fink L., et al. Invivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI (-PEG)/siRNA complexes. Toxicol Appl Toxicol 2009, 236:97-108.
24. Wolfrum C., Shi S., Jayaprakash K.N., et al. Mechanisms and optimization of invivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25:1149-1157.
25. Akinc A., Querbes W., De S., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010, 18:1357-1364.
26. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25:55-71.
27. Bazile D., Prud'homme C., Bassoullet M.T., et al. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84:493-498.
28. Martina M.S., Nicolas V., Wilhelm C., et al. The invitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and macrophages. Biomaterials 2007, 28:4143-4153.
29. Jarad G., Miner J.H. Update on the glomerular filtration barrier. Curr Opin Nephrol Hypertens 2009, 18:226.
30. Wartiovaara J., Öfverstedt L.G., Khoshnoodi J., et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 2004, 114:1475-1483.
31. Rappaport J., Hanss B., Kopp J.B., et al. Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int 1995, 47:1462-1469.
32. Lee H., Lytton-Jean A.K.R., Chen Y., et al. Molecularly self-assembled nucleic acid nanoparticles for targeted invivo siRNA delivery. Nat Nanotechnol 2012, 7:389-393.
33. Rozema D.B., Lewis D.L., Wakefield D.H., et al. Dynamic PolyConjugates for targeted invivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci 2007, 104:12982-12987.
34. Yu B., Zhao X., Lee L.J., et al. Targeted delivery systems for oligonucleotide therapeutics. AAPS J 2009, 11:195-203.
35. Salvati A., Pitek A.S., Monopoli M.P., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8:137-143.
36. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta-Rev Cancer 2011, 1816:232-246.
37. Shim M.S., Kwon Y.J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv Drug Deliv Rev 2012, 64:1046-1059.
38. Barquinero J., Eixarch H., Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther 2004, 11:S3-S9.
39. Vandenbroucke R.E., De Geest B.G., Bonné S., et al. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly (β-amino esters). J Gene Med 2008, 10:783-794.
40. Kanasty R., Dorkin J.R., Vegas A., et al. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
41. Juliano R., Alam M.R., Dixit V., et al. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008, 36:4158-4171.
42. Aigner A. Nonviral invivo delivery of therapeutic small interfering RNAs. Curr Opin Mol Ther 2007, 9:345-352.
43. Braasch D.A., Jensen S., Liu Y., et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003, 42:7967-7975.
44. Chiu Y.L., Rana T.M. siRNA function in RNAi: a chemical modification analysis. RNA 2003, 9:1034-1048.
45. Dande P., Prakash T.P., Sioufi N., et al. Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications. J Med Chem 2006, 49:1624-1634.
46. Hall A.H., Wan J., Shaughnessy E.E., et al. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 2004, 32:5991-6000.
47. Santel A., Aleku M., Keil O., et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006, 1:1222-1234.
48. Hayes M.E., Drummond D.C., Hong K., et al. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta Biomembr 2006, 1758:429-442.
49. Khoury M., Louis-Plence P., Escriou V., et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis Rheum 2006, 54:1867-1877.
50. Zuhorn I.S., Oberle V., Visser W.H., et al. Phase behavior of cationic amphiphiles and their mixtures with helper lipid influences lipoplex shape, DNA translocation, and transfection efficiency. Biophys J 2002, 83:2096-2108.
51. Landen C.N., Chavez-Reyes A., Bucana C., et al. Therapeutic EphA2 gene targeting invivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
52. Wu S.Y., McMillan N.A. Lipidic systems for invivo siRNA delivery. AAPS J 2009, 11:639-652.
53. Sørensen D.R., Leirdal M., Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003, 327:761-766.
54. Bao Y., Jin Y., Chivukula P., et al. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm Res 2013, 30:342-351.
55. Lin S.Y., Zhao W.Y., Tsai H.C., et al. Sterically polymer-based liposomal complexes with dual-shell structure for enhancing the siRNA delivery. Biomacromolecules 2012, 13:664-675.
56. Aleku M., Schulz P., Keil O., et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008, 68:9788-9798.
57. Strumberg D., Schultheis B., Traugott U., et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 2012, 50:76.
58. Morrissey D.V., Lockridge J.A., Shaw L., et al. Potent and persistent invivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23:1002-1007.
59. Judge A.D., Robbins M., Tavakoli I., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119:661.
60. Shen H., Sun T., Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012, 19:367-373.
61. Akinc A., Zumbuehl A., Goldberg M., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569.
62. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8:1112-1120.
63. Wang X., Wang Y., Chen Z.G., et al. Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009, 41:1-11.
64. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
65. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 1999, 10:1068-1074.
66. Bellocq N.C., Pun S.H., Jensen G.S., et al. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003, 14:1122-1132.
67. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006, 34:322-333.
68. Bartlett D.W., Su H., Hildebrandt I.J., et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality invivo imaging. Proc Natl Acad Sci 2007, 104:15549-15554.
69. Urban-Klein B., Werth S., Abuharbeid S., et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA invivo. Gene Ther 2005, 12:461-466.
70. Philipp A., Zhao X., Tarcha P., et al. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjug Chem 2009, 20:2055-2061.
71. Grayson A.C., Doody A.M., Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery invitro. Pharm Res 2006, 23:1868-1876.
72. Navarro G., Sawant R.R., Essex S., et al. Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res 2011, 1:25-33.
73. Navarro G., Sawant R.R., Biswas S., et al. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine 2012, 7:65-78.
74. Sun T.M., Du J.Z., Yan L.F., et al. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 2008, 29:4348-4355.
75. Mao C.Q., Du J.Z., Sun T.M., et al. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials 2011, 32:3124-3133.
76. Liu X.Q., Xiong M.H., Shu X.T., et al. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol Pharm 2012, 9:2863-2874.
77. Mao C.Q., Xiong M.H., Liu Y., et al. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA Delivery. Mol Ther 2014, 24:964-973. 10.1038/mt.2014.18.
78. Singh M., Briones M., Ott G., et al. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci 2000, 97:811-816.
79. Jilek S., Merkle H.P., Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 2005, 57:377-390.
80. Luu Y.K., Kim K., Hsiao B.S., et al. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J Control Release 2003, 89:341-353.
81. Woodrow K.A., Cu Y., Booth C.J., et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009, 8:526-533.
82. Yang X.Z., Dou S., Sun T.M., et al. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release 2011, 156:203-211.
83. Shen S., Mao C.Q., Yang X.Z., et al. Cationic lipid-assisted polymeric nanoparticles-mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma. Mol Pharm 2014, 11:2612-2622. 10.1021/mp400714z.
84. Jeong J.H., Mok H., Oh Y.K., et al. siRNA conjugate delivery systems. Bioconjug Chem 2008, 20:5-14.
85. Soutschek J., Akinc A., Bramlage B., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
86. Chiu Y.L., Ali A., Chu C., et al. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004, 11:1165-1175.
87. Moschos S.A., Jones S.W., Perry M.M., et al. Lung delivery studies using siRNA conjugated to TAT (48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007, 18:1450-1459.
88. Cesarone G., Edupuganti O.P., Chen C.P., et al. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug Chem 2007, 18:1831-1840.
89. Xia C.F., Zhang Y., Zhang Y., et al. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007, 24:2309-2316.
90. Chu T.C., Twu K.Y., Ellington A.D., et al. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006, 34:e73.
91. Simpson R.J., Lim J.W.E., Moritz R.L., et al. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009, 6:267-283.
92. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006, 55:808-818.
93. Ratajczak J., Miekus K., Kucia M., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20:847-856.
94. Valadi H., Ekström K., Bossios A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
95. Mittelbrunn M., Gutiérrez-Vázquez C., Villarroya-Beltri C., et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2011, 2:282.
96. Montecalvo A., Larregina A.T., Shufesky W.J., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766.
97. Alvarez-Erviti L., Seow Y., Yin H.F., et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29:341-345.
98. El-Andaloussi S., Lee Y., Lakhal-Littleton S., et al. Exosome-mediated delivery of siRNA invitro and invivo. Nat Protoc 2012, 7:2112-2126.
99. Goodman R.P., Schaap I.A.T., Tardin C.F., et al. Rapid chiral assembly of rigid DNA building blocks for molecular nanofabrication. Science 2005, 310:1661-1665.